logo

For the Inventor, By the Inventor

Pepper Pike, OH, United States of America

Vamsidhar Velcheti

This inventor holds 18 USPTO granted patents and 2 published patent applications and 2 EPO patents, primarily in Cancer Prognostics. Top assignees: Case Western Reserve University, The Cleveland Clinic Foundation. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vamsidhar Velcheti. Retrieved from https://idiyas.com/inventor/vamsidhar-velcheti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 94.4

 

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 107(Granted Patents)


Company Filing History:

goldMedal18 out of 1,368 
 
Case Western Reserve University
 patents
silverMedal6 out of 1,075 
 
The Cleveland Clinic Foundation
 patents
where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Immunotherapy Response
Radiomic Features
Tumor Infiltrating Lymphocytes
Non-Small Cell Lung Cancer
Recurrence Prediction
Hematoxylin and Eosin
Computed Tomography
PD-L1 Expression
Cancer Nuclei
Adjuvant Chemotherapy
Vessel Tortuosity
Pathomic Features
18 patents (USPTO):Explore Patents
1. RE50999 - PREDICTING RESPONSE TO IMMUNOTHERAPY USING COMPUTER EXTRACTED FEATURES RELATING TO SPATIAL ARRANGEMENT OF TUMOR INFILTRATING LYMPHOCYTES IN NON-SMALL CELL LUNG CANCER (2026-08-18),
2. RE50888 - Predicting response to immunotherapy using computer extracted features of cancer nuclei from hematoxylin and eosin (HandE) stained images of non-small cell lung cancer (NSCLC) (2026-05-12),
3. 11574404 - Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC) (2023-02-07),
4. 11350901 - Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography (2022-06-07),
5. 11055844 - Predicting response to immunotherapy using computer extracted features of cancer nuclei from hematoxylin and eosin (HandE) stained images of non-small cell lung cancer (NSCLC) (2021-07-06),
6. 10956795 - Predicting recurrence in early stage non-small cell lung cancer (NSCLC) using spatial arrangement of clusters of tumor infiltrating lymphocytes and cancer nuclei (2021-03-23),
7. 10950351 - Methods and apparatus for predicting benefit from immunotherapy using tumoral and peritumoral radiomic features (2021-03-16),
8. 10902256 - Predicting response to immunotherapy using computer extracted features relating to spatial arrangement of tumor infiltrating lymphocytes in non-small cell lung cancer (2021-01-26),
9. 10846367 - Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic features (2020-11-24),
10. 10839513 - Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features (2020-11-17),
11. 10575774 - Predicting immunotherapy response in non-small cell lung cancer with serial radiomics (2020-03-03),
12. 10492723 - Predicting immunotherapy response in non-small cell lung cancer patients with quantitative vessel tortuosity (2019-12-03),
13. 10458895 - Predicting response to pemetrexed chemotherapy in non-small cell lung cancer (NSCLC) with baseline computed tomography (CT) shape and texture features (2019-10-29),
14. 10441225 - Predicting disease recurrence following trimodality therapy in non-small cell lung cancer using computed tomography derived radiomic features and clinico-pathologic features (2019-10-15),
15. 10441215 - Predicting immunotherapy response in non-small cell lung cancer with serial quantitative vessel tortuosity (2019-10-15),

Title: Innovations in Cancer Prognosis: The Contributions of Vamsidhar Velcheti

Introduction

Vamsidhar Velcheti is a notable innovator based in Pepper Pike, Ohio, recognized for his significant contributions to the field of medical imaging and cancer prognosis. With a remarkable portfolio of 16 patents, he focuses primarily on developing technologies that enhance predictions related to cancer recurrence and treatment efficacy.

Latest Patents

Among his latest patents is the innovation titled "Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC)." This patent describes a method where a processor is controlled to perform operations including accessing a digitized image of cancerous tissue, extracting radiomic features correlated with PD-L1 expression, and applying machine learning algorithms to predict the probability of cancer recurrence.

Another significant patent is related to "Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography." This invention aims to generate prognosis for NSCLC recurrence and assess the potential benefits of adjuvant chemotherapy by analyzing radiological images and extracting relevant radiomic features.

Career Highlights

Throughout his career, Vamsidhar has worked with prestigious institutions such as Case Western Reserve University and The Cleveland Clinic Foundation. His role in these organizations has allowed him to merge research with practical applications, advancing the understanding of cancer prognosis.

Collaborations

In his journey of innovation, Vamsidhar has collaborated with esteemed peers, including Anant Madabhushi and Xiangxue Wang. These collaborations have proven instrumental in enhancing the precision of his research and the development of groundbreaking technologies in cancer diagnostics.

Conclusion

Vamsidhar Velcheti's contributions to the field of cancer prognosis through his patents highlight the vital intersection of innovation and healthcare. His dedication to improving clinical outcomes for patients with non-small cell lung cancer sets a precedent for future research and development in medical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…